Published in Radiology on June 27, 2005
Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol (2009) 1.87
Elastic registration of multimodal prostate MRI and histology via multiattribute combined mutual information. Med Phys (2011) 1.54
Radiotherapy planning using MRI. Phys Med Biol (2015) 0.93
Concurrent segmentation of the prostate on MRI and CT via linked statistical shape models for radiotherapy planning. Med Phys (2012) 0.91
Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. Eur Radiol (2011) 0.85
Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia (2007) 0.77
Gold nanotheranostics: photothermal therapy and imaging of Mucin 7 conjugated antibody nanoparticles for urothelial cancer. Biomed Res Int (2015) 0.76
Qualitative evaluation of fiducial markers for radiotherapy imaging. Technol Cancer Res Treat (2014) 0.75
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol (2002) 2.63
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology (2013) 2.19
[Treatment of testicular cancer clinical stage I: watchful waiting, radiotherapy, chemotherapy or surgical intervention]. Ned Tijdschr Geneeskd (2006) 2.03
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol (2014) 1.77
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol (1998) 1.69
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging (2012) 1.57
Gender differences in stage-adjusted bladder cancer survival. Urology (2000) 1.55
Comparison of orthotopic sigmoid and ileal neobladders: continence and urodynamic parameters. Eur Urol (2004) 1.52
Cancer incidence in relatives of patients with testicular cancer in the eastern part of The Netherlands. Urology (2001) 1.51
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol (2006) 1.45
Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol (2013) 1.44
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Multiparametric MRI of the bladder: ready for clinical routine? AJR Am J Roentgenol (2014) 1.41
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology (2005) 1.40
Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology (2007) 1.39
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology (2009) 1.34
Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer (2013) 1.31
Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.31
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet (2010) 1.30
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol (2004) 1.30
Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2009) 1.30
Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol (2011) 1.29
Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol (2008) 1.26
IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys (2006) 1.26
Gender differences in stage distribution of bladder cancer. Urology (2000) 1.25
Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. Radiology (2005) 1.25
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology (2004) 1.22
Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology (2012) 1.20
Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. Radiology (2011) 1.19
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging (2004) 1.18
Variability in the description of morphologic and contrast enhancement characteristics of breast lesions on magnetic resonance imaging. Invest Radiol (2005) 1.17
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16
Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys (2008) 1.14
High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate (1999) 1.13
Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol (2004) 1.13
The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat (2004) 1.13
Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. Invest Radiol (2014) 1.12
Optimized dose regimen for whole-body FDG-PET imaging. EJNMMI Res (2013) 1.12
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol (1993) 1.12
Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol (1996) 1.12
Prostate cancer: computer-aided diagnosis with multiparametric 3-T MR imaging--effect on observer performance. Radiology (2012) 1.10
Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol (2007) 1.08
Bladder filling variation during radiation treatment of prostate cancer: can the use of a bladder ultrasound scanner and biofeedback optimize bladder filling? Int J Radiat Oncol Biol Phys (2006) 1.08
Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging (1999) 1.08
Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol (2006) 1.06
MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr Urol Rep (2013) 1.06